# EDGAR Filing Document

**Accession Number:** 0001613780
**File Stem:** 0001193125-23-058479
**Filing Date:** 2023-3
**Character Count:** 28506
**Document Hash:** d12feae8b14bf0a181709d80499c32cb
**Contains OCR:** False
**Source Format:** 

## Filing Content

## Filing Summary
**0001193125-23-058479.hdr.sgml**: 20230303

**ACCESSION NUMBER**: 0001193125-23-058479

**CONFORMED SUBMISSION TYPE**: 8-K

**PUBLIC DOCUMENT COUNT**: 18

**CONFORMED PERIOD OF REPORT**: 20230302

**ITEM INFORMATION**: Results of Operations and Financial Condition

**ITEM INFORMATION**: Regulation FD Disclosure

**ITEM INFORMATION**: Financial Statements and Exhibits

**FILED AS OF DATE**: 20230303

**DATE AS OF CHANGE**: 20230302

**FILER**: 

**COMPANY DATA:**
- **COMPANY CONFORMED NAME:** DBV Technologies S.A.
- **CENTRAL INDEX KEY:** 0001613780
- **STANDARD INDUSTRIAL CLASSIFICATION:** BIOLOGICAL PRODUCTS (NO DIAGNOSTIC SUBSTANCES) [2836]
- **IRS NUMBER:** 000000000
- **STATE OF INCORPORATION:** I0
- **FISCAL YEAR END:** 1231

**FILING VALUES:**
- **FORM TYPE:** 8-K
- **SEC ACT:** 1934 Act
- **SEC FILE NUMBER:** 001-36697
- **FILM NUMBER:** 23700849

**BUSINESS ADDRESS:**
- **STREET 1:** 177-181 AVENUE PIERRE BROSSOLETTE
- **CITY:** MONTROUGE
- **STATE:** I0
- **ZIP:** 92120
- **BUSINESS PHONE:** 33(0)155427878

**MAIL ADDRESS:**
- **STREET 1:** 177-181 AVENUE PIERRE BROSSOLETTE
- **CITY:** MONTROUGE
- **STATE:** I0
- **ZIP:** 92120

?xml version="1.0" encoding="utf-8" ? 8-K

------

### UNITED STATES

### SECURITIES AND EXCHANGE COMMISSION

#### Washington, D.C. 20549

------

### FORM 8-K

------

#### CURRENT REPORT

#### Pursuant to Section 13 or 15(d)

#### of the Securities Exchange Act of 1934

#### March 2, 2023

#### Date of Report (Date of earliest event reported)

------

## DBV Technologies S.A.

#### (Exact name of registrant as specified in its charter)

------

---

| | | |
|:---|:---|:---|
| **France** | **001-36697** | **Not applicable** |
| **(State or other jurisdiction**<br> **of incorporation)** | **(Commission**<br> **File Number)** | **(IRS Employer**<br> **Identification No.)** |

---

---

| | |
|:---|:---|
| **177-181 avenue Pierre Brossolette**<br> **92120 Montrouge France** | **Not Applicable** |
| **(Address of principal executive offices)** | **(Zip Code)** |

---

#### Registrant's telephone number, including area code: +33 1 55 42 78 78

------

Check the appropriate box below if the Form 8-K filing is intended to simultaneously satisfy the filing obligation of the registrant under any of the following provisions:

☐ Written communications pursuant to Rule 425 under the Securities Act (17 CFR 230.425)

☐ Soliciting material pursuant to Rule 14a-12 under the Exchange Act (17 CFR 240.14a-12)

☐ Pre-commencement communications pursuant to Rule 14d-2(b) under the Exchange Act (17 CFR 240.14d-2(b))

☐ Pre-commencement communications pursuant to Rule 13e-4(c) under the Exchange Act (17 CFR 240.13e-4(c))

Securities registered pursuant to Section 12(b) of the Act:

---

| | | |
|:---|:---|:---|
| **Title of each class** | **Trading<br>Symbol(s)** | **Name of each exchange**<br> **on which registered** |
| Ordinary shares, nominal value €0.10 per share | n/a | The Nasdaq Stock Market LLC \* |
| American Depositary Shares, each representing one- half of one ordinary share, nominal value €0.10 per share | DBVT | The Nasdaq Stock Market LLC |

---

**\*** Not for trading, but only in connection with the listing of the American Depositary Shares on The Nasdaq Stock Market LLC.

Indicate by check mark whether the registrant is an emerging growth company as defined in Rule 405 of the Securities Act of 1933 (§ 230.405 of this chapter) or Rule 12b-2 of the Securities Exchange Act of 1934 (§ 240.12b-2 of this chapter).

Emerging growth company ☐

If an emerging growth company, indicate by check mark if the registrant has elected not to use the extended transition period for complying with any new or revised financial accounting standards provided pursuant to Section 13(a) of the Exchange Act. ☐

------

---

| | |
|:---|:---|
| **Item 2.02.** | **Results of Operations and Financial Condition** |

---

On March 2, 2023, DBV Technologies S.A. (the "Company") issued a press release announcing the full year financial results and business update for the year ended December 31, 2022. A copy of the press release is being furnished as Exhibit 99.1 to this Current Report on Form 8-K.

The information contained in Item 2.02 in this Current Report on Form 8-K (including Exhibit 99.1) is being furnished and shall not be deemed "filed" for purposes of Section 18 of the Securities Exchange Act of 1934, as amended, (the "Exchange Act") or otherwise subject to the liabilities of that section, nor shall it be deemed incorporated by reference in any filing under the Securities Act of 1933, as amended, or the Exchange Act, except as expressly set forth by specific reference in such a filing.

---

| | |
|:---|:---|
| **Item 7.01** | **Regulation FD Disclosure** |

---

On March 2, 2023, the Company issued a press release announcing the filing of its Annual Report on Form 10-K for the year ended December 31, 2022 with the Securities and Exchange Commission and its Universal Registration Document for the year ended December 31, 2022 with the French market authority. A copy of the press release is being furnished as Exhibit 99.2 to this Current Report on Form 8-K.

The information contained in Item 7.01 in this Current Report on Form 8-K (including Exhibit 99.2) is being furnished and shall not be deemed "filed" for purposes of Section 18 of the Exchange Act or otherwise subject to the liabilities of that section, nor shall it be deemed incorporated by reference in any filing under the Exchange Act, except as expressly set forth by specific reference in such a filing.

---

| | |
|:---|:---|
| **Item 9.01** | **Financial Statements and Exhibits** |

---

(d) Exhibits

---

| | |
|:---|:---|
| **Exhibit**<br> **No.** | **Description** |
| 99.1 | [Press Release issued March 2, 2023](d408746dex991.htm) |
| 99.2 | [Press Release issued March 2, 2023](d408746dex992.htm) |
| 104 | Cover Page Interactive Data File (the cover page XBRL tags are embedded within the inline XBRL document) |

---

------

#### SIGNATURES
Pursuant to the requirements of the Securities Exchange Act of 1934, the registrant has duly caused this report to be signed on its behalf by the undersigned hereunto duly authorized.

---

| | | |
|:---|:---|:---|
| Date: March 2, 2023 | **DBV TECHNOLOGIES S.A.** | **DBV TECHNOLOGIES S.A.** |
|  | By: | /s/ Sébastien Robitaille |
|  | Name: | Sébastien Robitaille |
|  | Title: | Chief Financial Officer |

---

## Exhibit 99.1

**Exhibit 99.1**![LOGO](g408746page01aa.jpg)

---

| | |
|:---|:---|
| ![LOGO](g408746page01b.jpg) | ![LOGO](g408746page01c.jpg) <br>Montrouge, France, March 2, 2023 |

---

**DBV Technologies Reports Full Year 2022 Financial Results and Business Update** 

&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;• DBV completed EVOLVE, a 12-week caregiver and patient user experience
study of the modified Viaskin Peanut patch in peanut-allergic children ages 4 – 11 years old

&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;• DBV had $209.2 million in Cash and Cash Equivalents at December 31, 2022.

DBV Technologies (Euronext: DBV – ISIN: FR0010417345 – Nasdaq Stock Market: DBVT), a clinical-stage biopharmaceutical company, today reported financial results for the full year 2022. The audit procedures have been substantially completed by the Company's statutory auditors and financials – prepared under both US GAAP and IFRS for the purpose of Form 10-K and Universal Registration Document respectively – were approved by the Board of Directors on March 2, 2023.

**EVOLVE** 

DBV completed EVOLVE, a 12-week caregiver and patient user experience study of the modified Viaskin Peanut patch in 50 peanut allergic children ages 4 – 11-years old. The objective of EVOLVE was to evaluate the Instructions for Use (IFU) and ease of use for the modified Viaskin Peanut patch. The study concluded that the updated Viaskin Peanut IFU supported correct patch application, which included no lifting of the patch edges or detachment directly after application. Furthermore, EVOLVE concluded that the majority of parents/caregivers reported a positive ease of use experience with the modified Viaskin Peanut patch.

In EVOLVE, DBV also tested the functionality of an electronic patient diary (eDiary) to collect information on activities of daily living and patch adhesion scores. As previously announced, VITESSE will assess patch adhesion of the modified Viaskin Peanut patch and DBV will include a statistical test of adhesion in the VITESSE statistical analysis plan. EVOLVE verified that the eDiary tool can be used by caregivers in VITESSE to capture the adhesion data in support of a potential BLA application.

**Financial Highlights for the Full Year 2022** 

The Company's annual consolidated financial statements are prepared in accordance with both generally accepted accounting principles in the U.S. ("US GAAP") and International Financial Reporting Standards ("IFRS") as adopted by the European Union. Unless otherwise indicated, the financial figures in the Full Year 2022 Financial Highlights are presented under both U.S GAAP and IFRS financial statements, and commented using U.S. GAAP financial statements. Differences between US GAAP and IFRS consolidated financial statements are mainly due to discrepancies arising from the application of lease accounting standards.

------

![LOGO](g408746page01aa.jpg)

![LOGO](g408746page01b.jpg)

**Cash and Cash Equivalents** 

---

| | | | | | | | | |
|:---|:---|:---|:---|:---|:---|:---|:---|:---|
|  | **US GAAP** | **US GAAP** | **US GAAP** | **US GAAP** | ***IFRS*** | ***IFRS*** | ***IFRS*** | ***IFRS*** |
|  | Year ended December 31, | Year ended December 31, | Year ended December 31, | Year ended December 31, | *Year ended December 31,* | *Year ended December 31,* | *Year ended December 31,* | *Year ended December 31,* |
| In millions of USD | 2022 | 2022 | 2021 | 2021 | *2022* | *2022* | *2021* | *2021* |
|  **Net cash & cash equivalents at the beginning of the period** |  | **773** |  | **1964** | **** | ***773*** | **** | ***1964*** |
|  **Net increase / (decrease) in cash & cash equivalents, of which:** |  | **1319** |  | **(1191** | **** | ***1319*** | **** | ***(1191*** |
|  *Net cash flow used in operating activities* | | *(557* | | *(1082* | | *(514* | | *(1041* |
|  *Net cash flow used in investing activities* | | *(01* | | *(04* | | *(01* | | *(04* |
|  *Net cash flow provided by / (used in) financing activities* | | *1941* | | *03* | | *1899* | | *(39* |
|  *Effect of exchange rate changes on cash & cash equivalents* | | *(65* | | *(107* | | *(65* | | *(107* |
|  **Net cash & cash equivalents at the end of the period** |  | **2092** |  | **773** | **** | ***2092*** | **** | ***773*** |

---

Cash and cash equivalents amount to $209,2 million as of December 31, 2022, compared to $77,3 million as of December 31, 2021, which is an increase by $131,9 million due to:

(1) $194,1 million due to financing activities, mainly from ATM Program in May 2022 ($14,1 million, net
of transaction costs), then from private investment in public equity ($180,4 million, net of transaction costs);

(2) $26,1 million reimbursed by French tax administration for research tax credits related to years 2019,
2020, and 2021;

And partially offset by :

(3) $81,8 million of cash used for operations, before $26,1 million reimbursement of research tax
credits. This is a decrease of 24% compared to prior year reflecting the cost containment measures that has been continuously maintained since their implementation in 2020.

------

![LOGO](g408746page01aa.jpg)

![LOGO](g408746page01b.jpg)

---

| | | | | | | | | | | | | |
|:---|:---|:---|:---|:---|:---|:---|:---|:---|:---|:---|:---|:---|
|  | **US GAAP** | **US GAAP** | **US GAAP** | ***IFRS*** | ***IFRS*** | ***IFRS*** | ***IFRS*** | ***IFRS*** | ***IFRS*** | ***IFRS*** | ***IFRS*** |  |
| In millions of USD | FY22 | FY21 | FY20 | *FY22* | *FY22* |  | *FY21* | *FY21* |  | *FY20* | *FY20* |  |
|  Net cash flow used in operating activities | 557 | 1082 | 1656 | | *514* | | | *1041* | | | *160.9* | |
|  Reimbursements of Research Tax Credits | 261 |  |  | | *261* | | | *—* | | | *—* | |
|  Net cash flow used in operating activities, excluding reimbursements of Research Tax Credits | 818 | 1082 | 1656 | | *775* | | | *1041* | | | *1609* | |
|  **Compared to prior year** | **-264** | **-574** |  | **** | ***-266*** | **** | **** | ***-568*** | **** |  |  |  |
|  | **-24%** | **-35%** |  | **** | ***-26*** | *%*** | **** | ***-35*** | *%*** |  |  |  |

---

(4) $6,5 million negative impact of changes in exchange rates.

The Company's treasury position, stated in US Dollars, has benefited in the last quarter from a change in the Euro to US Dollar exchange rate. The company's activities and expenditures in the fourth quarter were in line with expectations and continue to reflect DBV's expense discipline.

**Operating Income** 

---

| | | | | | | | | | | | | |
|:---|:---|:---|:---|:---|:---|:---|:---|:---|:---|:---|:---|:---|
|  | **US GAAP** | **US GAAP** | **US GAAP** | **US GAAP** | ***IFRS*** | ***IFRS*** | ***IFRS*** | ***IFRS*** | ***IFRS*** | ***IFRS*** | ***IFRS*** | ***IFRS*** |
|  | Year ended December 31, | Year ended December 31, | Year ended December 31, | Year ended December 31, | *Year ended December 31,* | *Year ended December 31,* | *Year ended December 31,* | *Year ended December 31,* | *Year ended December 31,* | *Year ended December 31,* | *Year ended December 31,* | *Year ended December 31,* |
| In millions of USD | 2022 | 2021 | Variation | Variation | *2022* | *2022* | *2021* | *2021* | *Variation* | *Variation* | *Variation* | *Variation* |
|  Research tax credits | 57 | 75 | -18 | -24% | | *57* | | *75* | | *-18* | | *-24 %* |
|  Other operating income | (09) | (18) | +09 | -51% | | *(09* | | *(18* | | *+0,9* | | *-51 %* |
|  **Produits opérationnels** | **48** | **57** | **-09** | **-15%** | **** | ***48*** | **** | ***57*** | **** | ***-09*** | **** | ***-15*** *%*** |

---

Operating income amounts to $4,8 million as of December 31, 2022, compared to $5,7 million as of December 31, 2021, which is a decrease by $0,9 million due to:

&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;(1) A decrease in 2022 research tax credit by $1.8 million compared to 2021. This reflects the impact of the
global restructuring plan initiated in 2020 and completed in 2021 which has impacted the expenses eligible to the research tax credit.

&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;(2) Partially offset by the variance in other operating income that consists of revenues recognized in advance of
the completion of the collaboration agreement with Nestlé Health Science ("NHS").

------

![LOGO](g408746page01aa.jpg)

![LOGO](g408746page01b.jpg)

**Operating Expenses**

---

| | | | | | | | | | | | | | | |
|:---|:---|:---|:---|:---|:---|:---|:---|:---|:---|:---|:---|:---|:---|:---|
|  | **US GAAP** | **US GAAP** | **US GAAP** | **US GAAP** | **US GAAP** | **US GAAP** | ***IFRS*** | ***IFRS*** | ***IFRS*** | ***IFRS*** | ***IFRS*** | ***IFRS*** | ***IFRS*** | ***IFRS*** |
| In millions of USD | Year ended December 31, | Year ended December 31, | Year ended December 31, | Year ended December 31, | Year ended December 31, | Year ended December 31, | *Year ended December 31,* | *Year ended December 31,* | *Year ended December 31,* | *Year ended December 31,* | *Year ended December 31,* | *Year ended December 31,* | *Year ended December 31,* | *Year ended December 31,* |
| In millions of USD | 2022 | 2022 | 2021 | 2021 | Variation | Variation | *2022* | *2022* | *2021* | *2021* | *Variation* | *Variation* | *Variation* | *Variation* |
|  Research & Development |  | 755 |  | 703 | +52 | +7% | | *752* | | *701* | | *+5,1* | | *+7 %* |
|  Sales & Marketing |  | 16 |  | 44 | -28 | -63% | | *16* | | *44* | | *-28* | | *-65 %* |
|  General & Administrative |  | 243 |  | 305 | -62 | -20% | | *242* | | *304* | | *-61* | | *-20 %* |
|  Restructuring |  |  |  | (09) | +09 | -100% | | *—* | | *(09* | | *+0,9* | | *-100 %* |
|  **Total operating expenses** |  | **1015** |  | **1043** | **-28** | **-3%** | **** | ***1010*** | **** | ***1040*** | **** | ***-29*** | **** | ***-3*** *%*** |
|  *including personnel expenses* | | *240* | | *311* | *-71* | -23% | | *240* | | *311* | | *-71* | | *-23 %* |

---

Operating expenses amount to $101,5 million as of December 31, 2022, compared to $104,3 million as of December 31, 2021, which is a decrease by $2,8 million mainly due to the decrease in personnel expenses as a result of the global restructuring plan that was announced in 2020 and completed in the course of 2021. The average number of employees was 86 for the year ended December 31, 2022, compared to 101 and 270 for the years ended December 31, 2021 and 2020 respectively.

This reduction in our operating expenses also reflects the strict financial discipline maintained across all services to focus our resources on the support of our clinical trial objectives.

**Net Loss and Net Loss per Share** 

---

| | | | | | | | | | | | | |
|:---|:---|:---|:---|:---|:---|:---|:---|:---|:---|:---|:---|:---|
|  | **US GAAP** | **US GAAP** | **US GAAP** | **US GAAP** | ***IFRS*** | ***IFRS*** | ***IFRS*** | ***IFRS*** | ***IFRS*** | ***IFRS*** | ***IFRS*** | ***IFRS*** |
|  | Year ended December 31, | Year ended December 31, | Year ended December 31, | Year ended December 31, | *Year ended December 31,* | *Year ended December 31,* | *Year ended December 31,* | *Year ended December 31,* | *Year ended December 31,* | *Year ended December 31,* | *Year ended December 31,* | *Year ended December 31,* |
|  | 2022 | 2021 | Variation | Variation | *2022* | *2022* | *2021* | *2021* | *Variation* | *Variation* | *Variation* | *Variation* |
|  Net (loss) in millions of USD | (963) | (978) | +15 | -2% | | *(960)* | | *(981)* | | *+2,0* | | *-2 %* |
|  Basic / diluted net (loss) per share in USD | (124) | (178) | +05 | -30% | | *(124)* | | *(179)* | | *+0,6* | | *-31 %* |

---

Net result for the year ended December 31, 2022, is a loss amounting to $96,3 million compared to a loss amounting to $97,8 million for the year ended December 31, 2021.

On a per share basis, net loss (based on the weighted average number of shares outstanding over the period) is $1.24 for the year ended December 31, 2022.

------

![LOGO](g408746page01aa.jpg)

![LOGO](g408746page01b.jpg)

**Conference Call Information** DBV will host a conference call and live audio webcast today, Thursday, March 2, 2023, at 5:00 p.m. ET to report fourth quarter 2022 financial results and provide a

business update.

Attendees may access the call via the below teleconferencing numbers and asking to join the DBV Technologies call:

&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;• United States: 1-866-777-2509

&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;• International: 1-412-317-5413

A live webcast of the call will be available on the Investors & Media section of the Company's website: <u>https://www.dbv-technologies.com/investor-relations/</u> A replay of the presentation will also be available on DBV's website after the event

------

![LOGO](g408746page01aa.jpg)

![LOGO](g408746page01b.jpg)

**CONDENSED STATEMENT OF CONSOLIDATED FINANCIAL POSITION** 

---

| | | | | | | |
|:---|:---|:---|:---|:---|:---|:---|
|  | **US GAAP** | **US GAAP** | ***IFRS*** | ***IFRS*** | ***IFRS*** | ***IFRS*** |
|  | Year ended December 31, | Year ended December 31, | *Year ended December 31,* | *Year ended December 31,* | *Year ended December 31,* | *Year ended December 31,* |
| In millions of USD | 2022 | 2021 | *2022* | *2022* | *2021* | *2021* |
|  **Assets** | **2465** | **1467** | | ***2465*** | | ***1463*** |
|  of which cash & cash equivalents | 2092 | 773 | | *2092* | | *773* |
|  **Liabilities** | **521** | **474** | | ***520*** | | ***473*** |
|  **Shareholders' equity** | **1945** | **993** | | ***1945*** | | ***990*** |
|  of which net result | (963) | (978) | | *(960* | | *(981* |

---

**CONDENSED STATEMENT OF CONSOLIDATED OPERATIONS AND COMPREHENSIVE LOSS** 

---

| | | | | | | |
|:---|:---|:---|:---|:---|:---|:---|
|  | **US GAAP** | **US GAAP** | ***IFRS*** | ***IFRS*** | ***IFRS*** | ***IFRS*** |
| In millions of USD | Year ended December 31, | Year ended December 31, | *Year ended December 31,* | *Year ended December 31,* | *Year ended December 31,* | *Year ended December 31,* |
| In millions of USD | 2022 | 2021 | *2022* | *2022* | *2021* | *2021* |
|  **Revenues** | **48** | **57** | **** | ***48*** | **** | ***57*** |
|  Research & Development | (755) | (703) | | *(752* | | *(701* |
|  Sales & Marketing | (16) | (44) | | *(16* | | *(44* |
|  General & Administrative | (243) | (305) | | *(242* | | *(304* |
|  Restructuring income/(expenses) |  | 09 | | *—* | | *09* |
|  **Operating expenses** | **(1015)** | **(1043)** | **** | ***(1010*** | **** | ***(1040*** |
|  Finance income/(expenses) | 04 | 04 | | *03* | | *(02* |
|  Income tax | (01) | 04 | | *(01* | | *04* |
|  **Net gain/(loss)** | **(963)** | **(978)** | **** | ***(960*** | **** | ***(981*** |
|  Résultat de base et dilué par action ($/action) | (124) | (178) | | *(124* | | *(179* |

---

------

![LOGO](g408746page01aa.jpg)

![LOGO](g408746page01b.jpg)

**CONDENSED STATEMENT OF CONSOLIDATED CASH FLOW** 

---

| | | | | | | |
|:---|:---|:---|:---|:---|:---|:---|
|  | **US GAAP** | **US GAAP** | ***IFRS*** | ***IFRS*** | ***IFRS*** | ***IFRS*** |
|  | Year ended December 31, | Year ended December 31, | *Year ended December 31,* | *Year ended December 31,* | *Year ended December 31,* | *Year ended December 31,* |
| In millions of USD | 2022 | 2021 | *2022* | *2022* | *2021* | *2021* |
|  Net cash flows provided / (used) in operating activities | (557) | (1082) | | *(514* | | *(1041* |
|  Net cash flows provided / (used) in investing activities | (01) | (04) | | *(01* | | *(04* |
|  Net cash flows provided / (used) in financing activities | 1941 | 03 | | *1899* | | *(39* |
|  Effect of exchange rate changes on cash & cash equivalents (US GAAP presentation) | (65) | (107) |  |  |  |  |
|  **Net increase / (decrease) in cash & cash equivalents** | **1319** | **(1191)** | | ***1384*** | | ***(1084*** |
|  Net cash & cash equivalents at the beginning of the period | 773 | 1964 | | *773* | | *1964* |
|  Effect of exchange rate changes on cash & cash equivalents (IFRS presentation) |  |  | | *(65* | | *(107* |
|  **Net cash & cash equivalents at the end of the period** | **2092** | **773** | | ***2092*** | | ***773*** |

---

**About DBV Technologies** 

DBV Technologies is developing Viaskin<sup>™</sup>, an investigational proprietary technology platform with broad potential applications in immunotherapy. Viaskin is based on epicutaneous immunotherapy, or EPIT<sup>™</sup>, and is DBV Technologies' method of delivering biologically active compounds to the immune system through intact skin. With this new class of non-invasive product candidates, the Company is dedicated to safely transforming the care of food allergic patients. DBV Technologies' food allergies programs include ongoing clinical trials of Viaskin Peanut. DBV Technologies has global headquarters in Montrouge, France, and North American operations in Basking Ridge, NJ. The Company's ordinary shares are traded on segment B of Euronext Paris (Ticker: DBV, ISIN code: FR0010417345) and the Company's ADSs (each representing one-half of one ordinary share) are traded on the Nasdaq Global Select Market (Ticker: DBVT).

**Forward Looking Statements** 

This press release may contain forward-looking statements and estimates, including statements regarding DBV's forecast of its cash runway, designs of DBV's anticipated clinical trials, DBV's planned regulatory and clinical efforts including timing and results of communications with regulatory agencies, the ability of any of DBV's product candidates, if approved, to improve the lives of patients with food allergies, and the outcome of any litigation. These forward-looking statements and estimates are not promises or guarantees and involve substantial risks and uncertainties. At this stage, DBV's

------

![LOGO](g408746page01aa.jpg)

![LOGO](g408746page01b.jpg)

product candidates have not been authorized for sale in any country. Among the factors that could cause actual results to differ materially from those described or projected herein include uncertainties associated generally with research and development, clinical trials and related regulatory reviews and approvals, including the impact of the COVID-19 pandemic, and DBV's ability to successfully execute on its budget discipline measures. A further list and description of risks and uncertainties that could cause actual results to differ materially from those set forth in the forward-looking statements in this press release can be found in DBV's regulatory filings with the French Autorité des Marchés Financiers ("AMF"), DBV's filings and reports with the U.S. Securities and Exchange Commission ("SEC"), including in DBV's Annual Report on Form 10-K for the year ended December 31, 2022, filed with the SEC on March 2, 2023, and future filings and reports made with the AMF and SEC by DBV. Existing and prospective investors are cautioned not to place undue reliance on these forward-looking statements and estimates, which speak only as of the date hereof. Other than as required by applicable law, DBV Technologies undertakes no obligation to update or revise the information contained in this Press Release.

**Investor Contact** 

Anne Pollak

DBV Technologies

+1 857-529-2363

anne.pollak@dbv-technologies.com

**Media Contact** 

Angela Marcucci

DBV Technologies

+1 646-842-2393

<u>angela.marcucci@dbv-technologies.com</u> 

Viaskin and EPIT are trademarks of DBV Technologies.

## Exhibit 99.2

**Exhibit 99.2**![LOGO](g408746page01aa.jpg)

---

| | |
|:---|:---|
| ![LOGO](g408746page01b.jpg) | ![LOGO](g408746page01c.jpg) <br>Montrouge, France, March 2, 2023 |

---

**DBV Technologies announces filing of 2022 Annual Report on Form 10-K and 2022 Universal Registration Document** 

DBV Technologies (Euronext: DBV – ISIN: FR0010417345 – Nasdaq Stock Market: DBVT), a clinical-stage biopharmaceutical company (the "Company"), today announced the filing of its Annual Report on Form 10-K for the year ended December 31, 2022, with the U.S. Securities and Exchange Commission ("SEC") and the filing of its 2022 Universal Registration Document ("URD") for the year ended December 31, 2022 with the French market authority, "Autorité des Marchés Financiers" ("AMF").

These documents can be accessed on the Investors section of the Company's website at <u>www.dbv-technologies.com</u>. In addition, the URD is available on the AMF's website at <u>www.amf-france.org</u> and the Form 10-K is available on the SEC's website at <u>www.sec.gov</u>.

Printed copies of both documents are available, free of charge, at the Company's headquarters and registered office located at 177-181 avenue Pierre Brossolette 92120 Montrouge, France.

**About DBV Technologies**

DBV Technologies is developing Viaskin<sup>™</sup>, an investigational proprietary technology platform with broad potential applications in immunotherapy. Viaskin is based on epicutaneous immunotherapy, or EPIT<sup>™</sup>, DBV's method of delivering biologically active compounds to the immune system through intact skin. With this new class of non-invasive product candidates, the Company is dedicated to safely transforming the care of food allergic patients. DBV's food allergies programs include ongoing clinical trials of Viaskin Peanut. DBV Technologies has global headquarters in Montrouge, France, and North American operations in Summit, NJ. The Company's ordinary shares are traded on segment B of Euronext Paris (Ticker: DBV, ISIN code: FR0010417345), part of the SBF120 index, and the Company's ADSs (each representing one-half of one ordinary share) are traded on the Nasdaq Global Select Market (Ticker: DBVT).

**Investor Contact** 

Anne Pollak

DBV Technologies

+1 857-529-2363

<u>anne.pollak@dbv-technologies.com</u>

------

![LOGO](g408746page01aa.jpg)

![LOGO](g408746page01b.jpg)

**Media Contact** 

Angela Marcucci

DBV Technologies

+1 646-842-2393

<u>angela.marcucci@dbv-technologies.com</u>